HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Takayoshi Ohkubo Selected Research

Renin

2/2015Association of aldosterone-to-renin ratio with hypertension differs by sodium intake: the Ohasama study.
8/2012Plasma renin activity and the aldosterone-to-renin ratio are associated with the development of chronic kidney disease: the Ohasama Study.
7/2012Aldosterone-to-renin ratio as a predictor of stroke under conditions of high sodium intake: the Ohasama study.
3/2011Aldosterone-to-renin ratio and home blood pressure in subjects with higher and lower sodium intake: the Ohasama study.
9/2002alpha-Adducin Gly460Trp polymorphism is associated with low renin hypertension in younger subjects in the Ohasama study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Takayoshi Ohkubo Research Topics

Disease

74Hypertension (High Blood Pressure)
04/2022 - 03/2002
24Cardiovascular Diseases (Cardiovascular Disease)
01/2022 - 09/2003
24Stroke (Strokes)
01/2021 - 09/2003
16Essential Hypertension
08/2019 - 02/2002
14Diabetes Mellitus
01/2020 - 04/2007
11Obesity
04/2019 - 12/2004
10Hypercholesterolemia
07/2018 - 12/2004
9White Coat Hypertension
08/2013 - 07/2005
8Chronic Renal Insufficiency
01/2021 - 12/2008
8Masked Hypertension
08/2013 - 08/2005
7Coronary Disease (Coronary Heart Disease)
01/2021 - 10/2002
6Atherosclerosis
11/2018 - 09/2014
5Heart Failure
12/2019 - 05/2008
4Myocardial Infarction
08/2018 - 10/2002
4Heart Diseases (Heart Disease)
08/2015 - 09/2006
3Insulin Resistance
01/2022 - 09/2010
3Proteinuria
01/2022 - 12/2008
3Neoplasms (Cancer)
10/2019 - 11/2018
3Overweight
04/2019 - 11/2015
3Hyperlipidemias (Hyperlipidemia)
04/2019 - 12/2008
3Body Weight (Weight, Body)
01/2018 - 10/2014
3Coronary Artery Disease (Coronary Atherosclerosis)
03/2016 - 09/2013
3Lacunar Stroke
04/2011 - 04/2007
2Dyslipidemias (Dyslipidemia)
03/2021 - 01/2015
2Cerebral Hemorrhage
02/2019 - 02/2006
2Type 2 Diabetes Mellitus (MODY)
01/2019 - 10/2004
2Cognitive Dysfunction
01/2018 - 09/2003
2Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
05/2017 - 04/2011
2Hyperaldosteronism (Conn Syndrome)
08/2012 - 03/2011
2Cerebral Infarction
01/2012 - 02/2006
2Renal Insufficiency (Renal Failure)
07/2010 - 10/2004
2Cerebrovascular Disorders (Cerebrovascular Occlusion)
06/2008 - 09/2003
2Vascular Diseases (Vascular Disease)
09/2003 - 12/2002
2Unstable Angina
12/2002 - 10/2002
1Periodontitis
06/2022
1Alveolar Bone Loss
06/2022
1Kidney Diseases (Kidney Disease)
01/2022
1COVID-19
10/2020
1Gout
01/2020
1Birth Weight (Birth Weights)
01/2020
1Hyperuricemia
01/2020

Drug/Important Bio-Agent (IBA)

57Antihypertensive Agents (Antihypertensives)IBA
04/2022 - 05/2002
9HDL CholesterolIBA
01/2018 - 01/2014
8SaltsIBA
02/2015 - 09/2002
7CholesterolIBA
01/2021 - 01/2012
7Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
10/2020 - 04/2003
7LipidsIBA
07/2018 - 09/2013
7AldosteroneIBA
02/2015 - 03/2011
6Angiotensin Receptor AntagonistsIBA
01/2022 - 04/2003
5ORALIT (ORS)IBA
06/2022 - 01/2017
5Calcium Channel Blockers (Blockers, Calcium Channel)IBA
01/2022 - 06/2008
5Triglycerides (Triacylglycerol)IBA
01/2022 - 01/2014
5Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
10/2020 - 03/2002
5CreatinineIBA
11/2018 - 12/2008
5PotassiumIBA
01/2018 - 07/2008
5ReninIBA
02/2015 - 09/2002
5mahuang-tangIBA
11/2010 - 08/2005
4Brain Natriuretic Peptide (Natrecor)FDA Link
07/2020 - 08/2015
4SodiumIBA
01/2018 - 03/2011
4C-Reactive ProteinIBA
01/2018 - 01/2015
4Dietary SodiumIBA
01/2017 - 03/2011
4CalciumIBA
03/2016 - 04/2003
3Blood Glucose (Blood Sugar)IBA
01/2022 - 01/2017
3Glucose (Dextrose)FDA LinkGeneric
01/2022 - 09/2010
3omega-Chloroacetophenone (Mace)IBA
01/2021 - 01/2017
3Indicators and Reagents (Reagents)IBA
01/2020 - 01/2015
3pro-brain natriuretic peptide (1-76)IBA
12/2019 - 08/2015
3Angiotensin IIIBA
08/2005 - 03/2002
2Pharmaceutical PreparationsIBA
01/2022 - 11/2012
24- (2- (4- hydroxybenzyl)- phenoxy)- N- methylbutylamineIBA
01/2021 - 08/2013
2Uric Acid (Urate)IBA
01/2021 - 01/2020
2A-factor (Streptomyces)IBA
01/2021 - 10/2004
2Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
11/2019 - 01/2014
21-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA
11/2018 - 03/2016
2HDL LipoproteinsIBA
01/2018 - 04/2015
2IrbesartanFDA LinkGeneric
10/2017 - 01/2016
2Amlodipine (Norvasc)FDA LinkGeneric
10/2017 - 06/2008
2DiureticsIBA
10/2017 - 11/2006
24- chloro- 3',6'- dimethyl- 2,2'- iminodibenzoate (TO 115)IBA
10/2017 - 04/2007
2Losartan (Cozaar)FDA LinkGeneric
01/2016 - 08/2005
2Valsartan (Vals)FDA Link
01/2016 - 08/2005
2Telmisartan (Micardis)FDA Link
01/2016 - 08/2005
2candesartanIBA
01/2016 - 08/2005
2Hemoglobins (Hemoglobin)IBA
01/2015 - 12/2004
2Fibrinogen (Factor I)FDA Link
01/2015 - 04/2007
2AlbuminsIBA
11/2012 - 02/2009
2AngiotensinogenIBA
06/2012 - 07/2002
2Prorenin ReceptorIBA
04/2011 - 12/2009
2Peptides (Polypeptides)IBA
07/2010 - 05/2008
2AdrenomedullinIBA
07/2010 - 09/2008
2Proteins (Proteins, Gene)FDA Link
02/2009 - 06/2008
2urotensin IIIBA
05/2008 - 10/2004
1antiarrhythmic peptide (AAP)IBA
06/2022
11,4-dihydropyridine (dihydropyridine)IBA
01/2022

Therapy/Procedure

10Therapeutics
01/2022 - 04/2003
2Ambulatory Care (Outpatient Care)
03/2021 - 09/2004
2Palliative Care (Palliative Therapy)
01/2019 - 11/2018
2Activities of Daily Living (ADL)
05/2018 - 02/2016
2Ligation
12/2009 - 05/2008
1Blood Pressure Monitors
01/2021